Skip to main content

COVID 19 Updates from RheumNow

Protective Effects of Colchicine in Non-Hospitalized COVID-19

A press release from the Montreal Heart Institute has announced that the COLCORONA clinical trial has provided evidence of the protective effect of colchicine; demonstrating a 21% reduced risk of death or hospitalizations in patients with COVID-19 compared to placebo. 

RheumNow Podcast – Don’t Hold the Benlysta, Take the Vaccine (1.22.2021)

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com, with more than a dozen items to review on this week's podcast.

NEJM: Early Combo Monoclonal Antibody Therapy in COVID-19

NEJM has published the interim analysis of the REGN-COV2 trial, wherein an antibody cocktail reduced viral loads with less clinical consequences. 

Combo Anti-Spike Protein Antibody for Mild to Moderate COVID-19

JAMA has published the BLAZE-1 study, showing significant SARS-CoV-2 viral load reduction at day 11 and less COVID-19 progression when combination anti-spike monoclonal antibody therapy (bamlanivimab and etesevimab) was given to mild to moderate, non-hospitalized COVID-19 patients.

Inequities in Telemedicine During COVID-19

MedPage Today

Health equity in the telehealth age has assumed added importance since the COVID-19 pandemic began. The Federal Communications Commission estimates that about 21 million Americans don't have access to the Internet in their homes. Other sources estimate it is closer to 162 million.

Travel During COVID-19 Pandemic

The CDC has addressed the effects and the issues of domestic and international travel on its website.  Below is a sampling of key advice.

2020 Rheumatology Year in Review

2020 was historic, memorable and game-changing. Under the cloud of COVID-19, there were many significant and memorable advances and setbacks for the rheumatology world. In our accounting of most read articles for 2020, (not surprisingly) 17/20 were COVID-related.

RheumNow Podcast – Lights, Camera, Zoom (1.8.2021)

Dr. Jack Cush reviews the news, journal articles and favorite blogs from this past week on RheumNow.com.

Zoomatology – Present in Absentia

Zoom has become the slam dunk answer to the pandemic. With zoom you can avoid congregations, but still attend and belong.  Because of zoom you can sustain your business and continue medical care.  With zoom, learning moved from the classroom to the dining room for all.

COVID-19 Vaccination - Phase Ib Begins

The U.S. Centers for Disease Control and Prevention (CDC) has issued a timeline guidance document on when, how and who should get the commercially available COVID-19 vaccines. 

Telemedicine Less Utilized in the South and Urban Areas

MMWR has reported on a July 2020 survey study from 1,009 Health Resources and Services Administration–funded health centers showing that urban Health centers were more likely to provide virtual visits than those in rural areas.

Plaquenil Does Not Protect Lupus Patients from COVID-19 (Best of 2020)

Editor's note: This article originally appeared May 14, 2020, and is being shared again as part of RheumNow's "Best of 2020".

Social

Protective Effects of Colchicine in Non-Hospitalized COVID-19 A press release from the Montreal Heart Institute has announced that the COLCORONA clinical trial has provided evidence of the protective effect of colchicine. Read more: https://t.co/quo19EPJUQ https://t.co/B65RGButgm
Dr. John Cush RheumNow( View Tweet)
2 days 11 hours ago
After you receive the 2nd dose of the COVID vaccine, note that it takes 2 weeks after the second dose to achieve high antibody levels against COVID-19, underscoring the importance of continuing masking, physical distancing and hand hygiene https://t.co/ZsWIM9O3Iu
Dr. John Cush RheumNow( View Tweet)
2 days 18 hours ago
NEJM: Early Combo Monoclonal Antibody Therapy in COVID-19 NEJM has published the interim analysis of the REGN-COV2 trial, wherein an antibody cocktail reduced viral loads with less clinical consequences. https://t.co/Gdby5qmPNG

Dr. John Cush RheumNow( View Tweet)

3 days 9 hours ago
Combo Anti-Spike Protein Antibody for Mild to Moderate COVID-19 https://t.co/DuG7pI4jL9

Dr. John Cush RheumNow( View Tweet)

3 days 17 hours ago
Don’t Hold the Benlysta, Take the Vaccine https://t.co/yBWj2U4ZnZ

Dr. John Cush RheumNow( View Tweet)

4 days 11 hours ago
2 very large UK population studies (millions of pts) show there is no evidence that NSAID use yields harm in those infected with COVID related deaths. There is either no risk (HR 0.96; 0.80, 1.14) or a reduced risk (HR 0.78; 0.64, 0.94) in these studies. https://t.co/gazA83Ogis

Dr. John Cush RheumNow( View Tweet)

4 days 13 hours ago

COVID Vaccine Q & A - Dr Kevin Winthrop Dr. Cush interviews Dr. Kevin Winthrop (OHSU) on the use and caveats to COVID-19 vaccination in patients with rheumatic disease and taking biologic and DMARD therapies https://t.co/EJL6hVLnrp https://t.co/XOHk9T04rx

Dr. John Cush RheumNow( View Tweet)
5 days 15 hours ago
Don’t hold Benlysta for the COVID19 vaccine! Previous studies have shown that SLE pts on Benlysta (belimumab) still have good antibody response to vaccinations (including Prevnar14, PPSV23, flu and tetanus vaccines). ⁦@RheumNow⁩ https://t.co/4rFdcIKjkT
6 days 8 hours ago
Toci led to poorer outcomes in this study. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial | The BMJ https://t.co/95zaq2CEUU

Dr Philip Robinson philipcrobinson( View Tweet)

6 days 18 hours ago
Inequities in Telemedicine During COVID-19 Health equity in the telehealth age has assumed added importance since the COVID-19 pandemic began but what if you don't have access to reliable technology? The problem spreads beyond that though. https://t.co/L8nvUbOqHA https://t.co/SZSmerQGEY
Dr. John Cush RheumNow( View Tweet)
6 days 19 hours ago
×